Welcome to LookChem.com Sign In|Join Free
  • or
N-TERT-BUTOXYCARBONYL-4-(4-TOLUENESULFONYLOXYMETHYL)PIPERIDINE, also known as tert-Butyl 4-((tosyloxy)methyl)piperidine-1-carboxylate, is a chemical compound that serves as an intermediate in the synthesis of biologically active molecules. It is characterized by its structural complexity and potential for use in the development of pharmaceuticals with various applications.

166815-96-9

Post Buying Request

166815-96-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

166815-96-9 Usage

Uses

Used in Pharmaceutical Industry:
N-TERT-BUTOXYCARBONYL-4-(4-TOLUENESULFONYLOXYMETHYL)PIPERIDINE is used as a chemical intermediate for the preparation of biologically active molecules with pharmacological applications. Its unique structure allows for the creation of compounds that can target specific biological pathways, potentially leading to the development of new drugs for various medical conditions.
As a key component in the synthesis of pharmaceuticals, N-TERT-BUTOXYCARBONYL-4-(4-TOLUENESULFONYLOXYMETHYL)PIPERIDINE plays a crucial role in advancing the field of drug discovery and development. Its versatility in chemical reactions enables researchers to explore a wide range of potential applications, from treating chronic diseases to addressing pressing health concerns.

Check Digit Verification of cas no

The CAS Registry Mumber 166815-96-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,6,8,1 and 5 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 166815-96:
(8*1)+(7*6)+(6*6)+(5*8)+(4*1)+(3*5)+(2*9)+(1*6)=169
169 % 10 = 9
So 166815-96-9 is a valid CAS Registry Number.
InChI:InChI=1/C18H27NO5S/c1-14-5-7-16(8-6-14)25(21,22)23-13-15-9-11-19(12-10-15)17(20)24-18(2,3)4/h5-8,15H,9-13H2,1-4H3

166815-96-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 10, 2017

Revision Date: Aug 10, 2017

1.Identification

1.1 GHS Product identifier

Product name N-Tert-Butoxycarbonyl-4-(4-Toluenesulfonyloxymethyl)Piperidine

1.2 Other means of identification

Product number -
Other names 1-(tert-Butoxycarbonyl)-4-(tosyloxymethyl)piperidine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:166815-96-9 SDS

166815-96-9Relevant academic research and scientific papers

Synthesis and evaluation of amide, sulfonamide and urea-benzisoxazole derivatives as potential atypical antipsychotics

Chen, Yin,Lan, Yu,Cao, Xudong,Xu, Xiangqing,Zhang, Juecheng,Yu, Minquan,Liu, Xin,Liu, Bi-Feng,Zhang, Guisen

, p. 831 - 838 (2015)

In this paper, we report the optimization of a series of novel, potential antipsychotic derivatives combining potent dopamine D2, D3 and serotonin 5-HT1A, 5-HT2A receptor affinities. The pharmacological features of compound 27 are a high affinity for dopamine D2, D3 and serotonin 5-HT1A, 5-HT2A receptors. Moreover it possesses low affinity for 5-HT2C and H1 receptors (to reduce the risk of obesity associated with chronic treatment) and hERG channels (to reduce the incidence of torsade des pointes). Furthermore, compound 27 inhibited apomorphine-induced climbing, MK-801-induced hyperactivity and DOI-induced head twitch without observable catalepsy at the highest dose tested in mice. Taken together, among the amide derivatives, we identified compound 27 as a potential antipsychotic lead candidate.

Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeutics

-

Paragraph 0380-0381, (2020/02/19)

Substituted -3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and related compounds, which are useful as inhibitors of ENPP1; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the ENPP1.

Method for synthesizing 1-azabicyclo[2, 2, 1]heptane and derivatives thereof

-

Paragraph 0019-0020, (2020/10/14)

The invention relates to the technical field of organic chemical synthesis, and particularly relates to a method for synthesizing 1-azabicyclo[2, 2, 1]pyridine and derivatives thereof. A hydroxyl group in 4-(1-hydroxymethyl)piperidine derivatives reacts with p-toluenesulfonyl chloride (TsCl) to be converted into an OTs group which is easy to leave, a tert-butyloxycarbonyl (-boc) protecting group on an N atom is removed under an acidic condition, a nucleophilic substitution ring closing reaction is performed under an alkaline condition, and extraction, solvent removal and concentration are carried out on a final reaction mixture to obtain the pure product 1-azabicyclo[2, 2, 1]heptane and derivatives thereof. The 1-azabicyclo[2, 2, 1]heptane and the derivatives thereof are obtained through three-step synthesis by reacting the 4-(1-hydroxymethyl)piperidine derivative with cheap and easily available common chemical reagents, and the method is discovered for the first time. The N-boc-4-(1-hydroxymethyl)piperidine used in the method is a cheap and easily available raw material, the synthesis method is simple, few in synthesis steps and easy to separate, and a large amount of target products can be synthesized.

Design, synthesis and evaluation of new classes of nonquaternary reactivators for acetylcholinesterase inhibited by organophosphates

Wei, Zhao,Bi, Huanglei,Liu, Yan-qin,Nie, Hui-fang,Yao, Lin,Wang, Sheng-zheng,Yang, Jun,Wang, Yong-an,Liu, Xueying,Zheng, Zhi-bing

supporting information, p. 681 - 688 (2018/09/29)

A new series of nonquaternary conjugates for reactivation of both nerve agents and pesticides inhibited hAChE were described in this paper. It was found that substituted salicylaldehydes conjugated to aminobenzamide through piperidine would produce efficient reactivators for sarin, VX and tabun inhibited hAChE, such as L6M1R3, L6M1R5 to L6M1R7, L4M1R3 and L4M1R5 to L4M1R7. The in vitro reactivation experiment for pesticides inhibited hAChE of these new synthesized oximes were conducted for the first time. Despite they were less efficient than obidoxime, some of them were highlighted as equal or more efficient reactivators in comparison to 2-PAM. It was found that introduction of peripheral site ligands could increase oximes’ binding affinity for inhibited hAChE in most cases, which resulted in greater reactivation ability.

Palladium-Catalyzed Atom-Transfer Radical Cyclization at Remote Unactivated C(sp3)?H Sites: Hydrogen-Atom Transfer of Hybrid Vinyl Palladium Radical Intermediates

Ratushnyy, Maxim,Parasram, Marvin,Wang, Yang,Gevorgyan, Vladimir

supporting information, p. 2712 - 2715 (2018/03/02)

A novel mild, visible-light-induced palladium-catalyzed hydrogen atom translocation/atom-transfer radical cyclization (HAT/ATRC) cascade has been developed. This protocol involves a 1,5-HAT process of previously unknown hybrid vinyl palladium radical intermediates, thus leading to iodomethyl carbo- and heterocyclic structures.

ANALOGUES OF 4H-PYRAZOLO[1,5-a] BENZIMIDAZOLE COMPOUND AS PARP INHIBITORS

-

Paragraph 0255, (2017/02/28)

Disclosed is a series of analogues of 4H-pyrazolo[1,5-α]benzimidazole compound as PARP inhibitors. In particular, disclosed in the invention is a compound as shown by formula (I) or a pharmaceutically acceptable salt thereof as a PARP inhibitor.

Conjugates of salicylaldoximes and peripheral site ligands: Novel efficient nonquaternary reactivators for nerve agent-inhibited acetylcholinesterase

Wei, Zhao,Liu, Yan-qin,Wang, Sheng-zheng,Yao, Lin,Nie, Hui-fang,Wang, Yong-an,Liu, Xue-Ying,Zheng, Zhi-bing,Li, Song

supporting information, p. 4497 - 4505 (2017/07/22)

A new family of nonquaternary reactivators for nerve agent-inhibited human acetylcholinesterase (hAChE) were designed, synthesized and tested in this paper. It was found that salicylaldoximes were able to quickly cleave the P–S bond of organophosphate and avoid the reinhibition phenomenon in the reactivation process, but they lacked reactivating ability due to poor affinity for AChE. Based on a dual site binding strategy, different peripheral site ligands of AChE were introduced to achieve extra affinity. The in vitro reactivation experiments demonstrated that some of the yielding conjugates exhibited similar or even superior ability to reactivate sarin-, VX- or tabun-inhibited hAChE in comparison with the mono- and bis-pyridinium aldoximes currently used. Moreover, due to greatly improved lipophilicity, these nonquaternary conjugates hold promise for the development of efficient centrally activating reactivators.

An alternative synthesis of Vandetanib (Caprelsa) via a microwave accelerated Dimroth rearrangement

Brocklesby, Kayleigh L.,Waby, Jennifer S.,Cawthorne, Chris,Smith, Graham

supporting information, p. 1467 - 1469 (2017/03/23)

Vandetanib is an orally available tyrosine kinase inhibitor used in the treatment of cancer. The current synthesis proceeds via an unstable 4-chloroquinazoline, using harsh reagents, in addition to requiring sequential protection and deprotection steps. In the present work, use of the Dimroth rearrangement in the key quinazoline forming step enabled the synthesis of Vandetanib in nine steps (compared to the previously reported 12–14).

A New Class of Fluorinated A2A Adenosine Receptor Agonist with Application to Last-Step Enzymatic [18F]Fluorination for PET Imaging

Lowe, Phillip T.,Dall'Angelo, Sergio,Mulder-Krieger, Thea,IJzerman, Adriaan P.,Zanda, Matteo,O'Hagan, David

, p. 2156 - 2164 (2017/10/07)

The A2A adenosine receptor belongs to a family of G-coupled protein receptors that have been subjected to extensive investigation over the last few decades. Due to their prominent role in the biological functions of the heart, lungs, CNS and brain, they have become a target for the treatment of illnesses ranging from cancer immunotherapy to Parkinson's disease. The imaging of such receptors by using positron emission tomography (PET) has also been of interest, potentially providing a valuable tool for analysing and diagnosing various myocardial and neurodegenerative disorders, as well as offering support to drug discovery trials. Reported herein are the design, synthesis and evaluation of two new 5′-fluorodeoxy-adenosine (FDA)-based receptor agonists (FDA-PP1 and FDA-PP2), each substituted at the C-2 position with a terminally functionalised ethynyl unit. The structures enable a synthesis of 18F-labelled analogues by direct, last-step radiosynthesis from chlorinated precursors using the fluorinase enzyme (5′-fluoro-5′-deoxyadenosine synthase), which catalyses a transhalogenation reaction. This delivers a new class of A2A adenosine receptor agonist that can be directly radiolabelled for exploration in PET studies.

PYRROLOPYRIDINE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF

-

Paragraph 0085; 0086, (2017/11/06)

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 166815-96-9